
1208PSafety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Conter, H J, MacDonald, L D, Fiset, S, Bramhecha, Y M, Chaney, M, Rosu, G NVolume:
30
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz253.034
Date:
October, 2019
Fichier:
PDF, 78 KB
english, 2019